With CD73 having led the way with 65 trials making progress through the clinical phases of development and CD39 having been close behind with 13 trials in play, the Adenosine landscape was bubbling with activity!

The 2^nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit returned as the premier event devoted to keeping the space moving while awaiting landmark results from AstraZeneca’s first-of-its-kind Phase 3 study into adenosine, by underpinning the biology of adenosine and directly linking this to improving the efficacy of drugs that targeted the adenosine pathway and accelerated the translation of therapeutics into the clinic. This included:

Where should we have been looking to determine reliable predictive biomarkers?

How could we have pinpointed the precise pathways and cascades that Adenosine’s therapeutic activity acted on and their fundamental functions in the development and treatment of cancer?

Adenosine-targeted treatments primarily targeted T-Cells, but as adenosine was essential for other immune system components, what impact did these therapeutics have on these other immune systems and cells?

And so much more…

With 21+ speakers, 3 days of content, and more networking opportunities than ever before, no stone was left unturned as CD73, CD39, A1AR, A2AR, interior adenosine pathways, improvement in trial design, biomarker validation, and clinical translation were exploited.

Experts in adenosine, immune checkpoint, tumor microenvironment, immune-oncology, and second-generation IO joined as they explored these core issues to accelerate more drugs to the late phases of study and hopefully approval!